Categories: News

New Tool Helps People Make Informed Decision on COVID-19 Vaccine

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

VIENNA, Va., July 7, 2021 /PRNewswire/ — With President Biden urging the nation to increase COVID-19 vaccinations, Allergy & Asthma Network, a national nonprofit patient education and advocacy organization, is releasing an innovative tool that will ease vaccine decision-making, especially for people of color and their doctors.

Allergy & Asthma Network partnered with SDMCentral, a LatinX-founded technology company in Madison, Wisconsin, to develop a Shared Decision Making tool that is conveniently designed for a desktop computer, tablet or mobile phone. It can be used in a clinic, home or other gathering place.

The Shared Decision Making took can be accessed here: https://allergyasthmanetwork.sdm.health/

“We know that most people want to make a decision about health care treatment as a partner with their doctors,” says Sally Schoessler, Allergy & Asthma Network’s Director of Education. “With COVID-19, owning the decision to get the vaccine is paramount.”

African Americans, Latinos and Native Americans have been disproportionately impacted by COVID-19. These groups are experiencing higher rates of cases, hospitalizations and deaths.

Shared Decision Making encourages people to take a more central and active role in their health by working with their doctors to participate in the choices involving treatments. Shared Decision Making is evidence-based and balances risks with results. Research shows that it gives patients more certainty and less anxiety about treatments, increases adherence and improves health outcomes.

The Shared Decision Making tool also helps clinicians better understand patient preferences and cultural values. People of color may want to know if the vaccine is safe and effective, get accurate information about side effects and find out if it is convenient to get the shot.

“Our goal is to use technology and smart content to reach out to patients, especially those of color, with this COVID-19 tool,” SDMCentral CEO Daniel Guerra, Jr. says.

About Allergy & Asthma Network
Allergy & Asthma Network is the leading nonprofit patient outreach, education, advocacy and research organization for people with asthma, allergies and related conditions. Our patient-centered network unites individuals, families, healthcare professionals, industry and government decision makers to improve health and quality of life for Americans with asthma and allergies. We specialize in making accurate medical information understandable to all while promoting evidence-based standards of care. Learn more at AllergyAsthmaNetwork.org.

About SDMCentral
SDMCentral, founded by a Madison, Wisconsin LatinX entrepreneur, creates Shared-Decision Making Aids for health care professionals and patients who want to be better partners in decisions about treatment plans for chronic disease.

Contact:
Gary Fitzgerald
Allergy & Asthma Network
gfitzgerald@allergyasthmanetwork.org 
703-641-9595

Daniel Guerra, Jr., CEO
SDM Analytics
dguerrajr@altuscampus.com  
608-212-2391

View original content:https://www.prnewswire.com/news-releases/new-tool-helps-people-make-informed-decision-on-covid-19-vaccine-301327429.html

SOURCE Allergy & Asthma Network

Staff

Recent Posts

PreveCeutical Announces Update to Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB:…

2 hours ago

Lam Research Corporation Announces March Quarter Financial Conference Call

FREMONT, Calif., April 2, 2025 /PRNewswire/ -- Lam Research Corp. (NASDAQ: LRCX) today announced that…

4 hours ago

Former Pfizer R&D Chief Mikael Dolsten Joins Formation Bio to Chair Drug Picking Committee and Co-Chair its Investment Advisory Committee

NEW YORK, April 2, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company revolutionizing drug development,…

4 hours ago

Siemens acquires Dotmatics to extend AI-powered software portfolio to Life Sciences

Acquisition of Dotmatics, a leader in Life Sciences R&D software for $5.1 billionExpands Siemens' market-leading…

4 hours ago

PerZeption Appoints CTO to Enhance Visual Function Assessments

BOSTON, April 2, 2025 /PRNewswire/ -- PerZeption Inc., a U.S. vision diagnostics startup dedicated to…

4 hours ago

Dotmatics Signs Definitive Agreement to be Acquired by Siemens Advancing a New Era of AI-Driven Innovation in Life Sciences

Siemens AG will acquire Dotmatics from global software investor Insight Partners for $5.1 billionAcquisition accelerates…

4 hours ago